Using Treg, Tr1, and Breg Expression Levels to Predict Clinical Responses to csDMARD Treatment in Drug-naive Patients With Rheumatoid Arthritis
In Vivo · 2023
DOI: 10.21873/invivo.13299 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2023. Verfasst von Ting-Yu Hsieh und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, National Defense Medical Center, Taipei, Taiwan, R.O.C. Hauptthemen laut MEDLINE: Antirheumatic Agents, B-Lymphocytes, Regulatory, Arthritis, Rheumatoid, Autoimmune Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: Regulatory T cells (Treg) play a crucial role in maintaining immune tolerance and preventing autoimmune diseases. Recent data also indicate that type 1 regulatory T (Tr1) and regulatory B (Breg) cells play an inhibitory (i.e., protective) role in autoimmune diseases. Conventional synthetic disease-modifying antirheumatic drugs (csDMARD) are a first-line therapy for rheumatoid arthritis (RA), and our aim was to predict clinical responses of this treatment using immunophenotyping. MATERIALS AND METHODS: We first detected the presence of immune cells in fresh blood from 16 healthy controls (HC) and 26 patients with RA (14 drug-naive and 12 csDMARD-experienced). Then, we recorded immunophenotypic changes in 14 drug-naive RA (naive RA) patients prior to csDMARD treatment (i.e., day 0) and after receiving treatment for 6 months. The observed changes were also compared with other clinical indicators, including the presence of anti-citrullinated peptide antibodies (anti-CCP), rheumatoid factor (RF) levels, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels. RESULTS: Naive RA patients had significantly lower Tregs than HC and csDMARD-experienced patients (both p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, National Defense Medical Center, Taipei, Taiwan, R.O.C.
- Biotech Research and Innovation Centre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- The Finsen Laboratory, Rigshospitalet/National University Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Institute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan, R.O.C.
- Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, R.O.C.
- Department of Translational Science, Massachusetts Laboratory for Engineering Medicine and Critical Data, Gloucester, MA, U.S.A.
Zitieren
APA
Hsieh, T. Y., Lui, S. W., Lu, J. W., Chen, Y. C., Lin, T. C., Jheng, W. L., Ho, Y. J., & Liu, F. C. (2023). Using Treg, Tr1, and Breg Expression Levels to Predict Clinical Responses to csDMARD Treatment in Drug-naive Patients With Rheumatoid Arthritis. In Vivo. https://doi.org/10.21873/invivo.13299
Vancouver
Hsieh TY, Lui SW, Lu JW, Chen YC, Lin TC, Jheng WL, et al. Using Treg, Tr1, and Breg Expression Levels to Predict Clinical Responses to csDMARD Treatment in Drug-naive Patients With Rheumatoid Arthritis. In Vivo. 2023. doi:10.21873/invivo.13299
BibTeX
@article{Hsieh2023,
author = {Hsieh, Ting-Yu and Lui, Shan-Wen and Lu, Jeng-Wei and Chen, Yen-Chen and Lin, Ting-Chun and Jheng, Wun-Long and Ho, Yi-Jung and Liu, Feng-Cheng},
title = {Using Treg, Tr1, and Breg Expression Levels to Predict Clinical Responses to csDMARD Treatment in Drug-naive Patients With Rheumatoid Arthritis},
journal = {In Vivo},
year = {2023},
doi = {10.21873/invivo.13299}
}
EUVIMED